Bids for Merck KGaA's generic biz break €4B

The latest round of bidding for the generic drug business of Germany's Merck KGaA pushed offers over the €4 billion ($5.4 billion) mark, according to a report in the Financial Times. Four bidding groups are still in the competition: Teva, Mylan, Actavis and a pair of private equity firms--Apax Partners and Bain Capital. Merck officials said as late as last Friday that no final decision on a sale had been made and the amount of financial information being made available to would-be buyers is still limited. Another round of bidding may be forthcoming.

- read the AFX report on the bidding

Related Articles:
New bid rumors heat up Merck KGaA stock. Report
Bidding war heats up for Merck KGaA generic unit. Report
Merck KGaA shortens list of bidders for drug unit. Report
Ranbaxy touts R&D abilities in new discovery pact. Report